In summary, this study demonstrates that TB001, a novel GCGR/GLP-1R co-agonist, can effectively alleviate renal fibrosis in pre-clinical models, likely by attenuating PERK-mediated ER stress and EMT in tubular cells. Here, GLP1R is linked to renal fibrosis.